Vijayaraghavan

About

Experienced Life Scientist with background in Biomedical and Bio-pharmaceutical Sciences. Accomplished teacher in the field of Laboratory medicine , laboratory animal sciences, experimental biology and regulatory guidelines pertaining to pre-clinical and clinical research. Mentor for Ph.D Scholars in the field of Biochemistry. Interested infectious disease, metabolic diseases, cancer vaccine development, clinical and pre clinical research.Experienced in Clinical Pathology, Histopathology, Electron Microscopy, Basic molecular biology, Basic Microbiology, Cell culture, Flow cytometry, Lab animal science, clinical biochemical studies, cancer vaccine development, laboratory diagnosis of infectious diseases. Awarded WHO (World Health Organization) fellowship in the field of experimental research using animal models. Trained in Good Laboratory Practice in United Kingdom. Completed Post doctoral training in the School of Medicine, Dept of Pathology and Laboratory Medicine, Emory University , Atlanta, GA, USA.

Employment

• University of Madras Research Scientist , VRRIBMS
  2013 - Present
• Emory University School of Medicine Post Doctoral Scientist
  2013 - 2014
• India Ministry of Health and Family Welfare Laboratory Officer
  1989 - 2012
• India Ministry of Health and Family Welfare Biologicals Standardization and Quality control
  1988 - 1989
• Indian Council for Medical Research Fellowship Research Assistant
  1986 - 1988

Education

• University of Madras Ph.D
  1997 - 2004

Projects & Funding

Projects & funding information is unavailable.

Publications (20)

• Naringin and 5-flurouracil suppress inflammatory cytokines in human skin cancer cell line
  Int. J. Res. Pharm. Sci., 2021, 12(1), 729-733 2021
  +Save
• Carvacrol inhibits osteoclast differentiation induced by RANKL in RAW264.7cells
  International J journal of research in pharmaceutical sciences 2020
  +Save
• Tumor membrane-based vaccine immunotherapy in combination with anti-CTLA-4 antibody confers protection against immune checkpoint resistant murine triple-negative breast cancer
  Human Vaccines and Immunotherapeutics 2020 DOI: 10.1080/21645515.2020.1754691
  +Save
• Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21WAF1/CIP1 and p27KIP1 in Cancer Cells
  VRR Institute of Biomedical Science, Affiliated to University of Madras, India 2019
  +Save
• Cell cycle arrest and cytotoxic effects of saha and rg7388 mediated through p21waf1/cip1and p27kip1in cancer cells
  Medicina (Lithuania) 2019 DOI: 10.3390/medicina55020030
  +Save
• Comparative effects of HDAC inhibitor SAHA and MDM2 inhibitor RG7388 in LNCap Prostrate Cancer cells,
  VRR Institute of Biomedical Science, Affiliated to University of Madras, India 2019
  +Save
• Differential mechanisms of cell death induced by HDAC inhibitor SAHA and MDM2 inhibitor RG7388 in MCF-7 cells, Page # 2-22,
  VRR Institute of Biomedical Science, Affiliated to University of Madras, India 2018
  +Save
• Effect of Histone Deacetylase (HDAC) Inhibitor on Gene Expression in LNCaP-MST and MCF-7 Cells
  VRR Institute of Biomedical Sciences, Affiliated to University of Madras, India 2018
  +Save
• Online journal of Bioinformatics
  Re-annotation of hypothetical proteins of Geobacter sulfurreducens PCA by integrated computation 2014
  +Save
• Good Laboratory Practice guidelines in academic and clinical research
  Journal of Pharmaceutical Research & Clinical Practice 2014
  +Save